Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25769641 | 0.81 | CYP2D6 (0.42) | CYP2D6CYP2C19MMP1MMP8ADH1B | |
| SCHEMBL21322186 | 0.79 | CYP2D6 (0.46) | CYP2D6CYP2C19MMP1MMP8ADH1B | |
| SCHEMBL15359354 | 0.75 | CYP2D6 (0.34) | CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL2297015 | 0.73 | — | — | |
| SCHEMBL22790562 | 0.71 | MAOA (0.34) | — | |
| SCHEMBL22788816 | 0.71 | GRM4 (0.30) | — | |
| SCHEMBL28469015 | 0.70 | PAOX (0.31) | — | |
| SCHEMBL2849739 | 0.70 | KDM4C (0.41) | CYP2D6MMP1 | |
| SCHEMBL18756282 | 0.70 | CYP2D6 (0.36) | CYP2D6CYP2C19 | |
| SCHEMBL19116861 | 0.70 | PTPN1 (0.36) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | CYP2D6 1973/4885CYP2C19 683/4885MMP1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.